Gastrointestinal stromal tumor surgery: Difference between revisions

Jump to navigation Jump to search
Line 4: Line 4:
{{Gastrointestinal stromal tumor}}
{{Gastrointestinal stromal tumor}}
==Overview==
==Overview==
The predominant therapy for gastrointestinal stromal tumor is surgical resection. Adjunctive chemotherapy/tyrosine Kinase Inhibitor therapy may be required.
The predominant therapy for gastrointestinal stromal tumor (GIST) is surgical resection. Surgical resection offers an opportunity to completely cure GIST. [[Laparoscopic]] and [[endoscopic]] resection are the most preferred route of surgery. Surgical [[resection]] of GIST include complete gross resection with an intact pseudocapsule and negative [[microscopic]] margins.
==Surgical Therapy==
==Surgical Therapy==


Surgery is the definitive therapy and typically the initial therapy for patients of GIST.
[[Surgery]] is the definitive therapy and typically the initial therapy for patients of gastrointestinal stromal tumor (GIST).
*Surgical resection offers an opportunity to completely cure GIST.
*Surgical resection offers an opportunity to completely cure GIST.
*Laparoscopic and endoscopic resection are the most preferred route of surgery. The indications for surgery include:<ref name="pmid23917593">{{cite journal |vauthors=Liang JW, Zheng ZC, Zhang JJ, Zhang T, Zhao Y, Yang W, Liu YQ |title=Laparoscopic versus open gastric resections for gastric gastrointestinal stromal tumors: a meta-analysis |journal=Surg Laparosc Endosc Percutan Tech |volume=23 |issue=4 |pages=378–87 |year=2013 |pmid=23917593 |doi=10.1097/SLE.0b013e31828e3e9d |url=}}</ref><ref name="pmid23898104">{{cite journal |vauthors=DE Vogelaere K, VAN DE Winkel N, Simoens C, Delvaux G |title=Intragastric SILS for GIST, a new challenge in oncologic surgery: first experiences |journal=Anticancer Res. |volume=33 |issue=8 |pages=3359–63 |year=2013 |pmid=23898104 |doi= |url=}}</ref><ref name="pmid23233005">{{cite journal |vauthors=De Vogelaere K, Hoorens A, Haentjens P, Delvaux G |title=Laparoscopic versus open resection of gastrointestinal stromal tumors of the stomach |journal=Surg Endosc |volume=27 |issue=5 |pages=1546–54 |year=2013 |pmid=23233005 |doi=10.1007/s00464-012-2622-8 |url=}}</ref><ref name="pmid28486486">{{cite journal |vauthors=Ye L, Wu X, Wu T, Wu Q, Liu Z, Liu C, Li S, Chen T |title=Meta-analysis of laparoscopic vs. open resection of gastric gastrointestinal stromal tumors |journal=PLoS ONE |volume=12 |issue=5 |pages=e0177193 |year=2017 |pmid=28486486 |pmc=5423634 |doi=10.1371/journal.pone.0177193 |url=}}</ref>
*[[Laparoscopic]] and [[endoscopic]] resection are the most preferred route of surgery. The indications for surgery include:<ref name="pmid23917593">{{cite journal |vauthors=Liang JW, Zheng ZC, Zhang JJ, Zhang T, Zhao Y, Yang W, Liu YQ |title=Laparoscopic versus open gastric resections for gastric gastrointestinal stromal tumors: a meta-analysis |journal=Surg Laparosc Endosc Percutan Tech |volume=23 |issue=4 |pages=378–87 |year=2013 |pmid=23917593 |doi=10.1097/SLE.0b013e31828e3e9d |url=}}</ref><ref name="pmid23898104">{{cite journal |vauthors=DE Vogelaere K, VAN DE Winkel N, Simoens C, Delvaux G |title=Intragastric SILS for GIST, a new challenge in oncologic surgery: first experiences |journal=Anticancer Res. |volume=33 |issue=8 |pages=3359–63 |year=2013 |pmid=23898104 |doi= |url=}}</ref><ref name="pmid23233005">{{cite journal |vauthors=De Vogelaere K, Hoorens A, Haentjens P, Delvaux G |title=Laparoscopic versus open resection of gastrointestinal stromal tumors of the stomach |journal=Surg Endosc |volume=27 |issue=5 |pages=1546–54 |year=2013 |pmid=23233005 |doi=10.1007/s00464-012-2622-8 |url=}}</ref><ref name="pmid28486486">{{cite journal |vauthors=Ye L, Wu X, Wu T, Wu Q, Liu Z, Liu C, Li S, Chen T |title=Meta-analysis of laparoscopic vs. open resection of gastric gastrointestinal stromal tumors |journal=PLoS ONE |volume=12 |issue=5 |pages=e0177193 |year=2017 |pmid=28486486 |pmc=5423634 |doi=10.1371/journal.pone.0177193 |url=}}</ref>
**Symptomatic patients with locally advanced or metastatic disease.
**Symptomatic patients with locally advanced disease.
**Large lesions and tumors that are technically resectable if the risks of morbidity are acceptable
**Large [[lesions]] and [[tumors]] that are technically resectable if the risks of [[morbidity]] are acceptable.


* Surgical resection of GIST include complete gross resection with with an intact pseudocapsule and negative microscopic margins.  
* Surgical [[resection]] of GIST include complete gross resection with an intact pseudocapsule and negative [[microscopic]] margins.  
* The GIST are highly vascular tumors and have a very fragile pseudocapsule and therefore the surgeon must be really careful regarding the risk of tumor rupture and subsequent peritoneal dissemination.  
* The GIST are highly [[vascular]] [[tumors]] and have a very fragile pseudocapsule and therefore the surgeon must be really careful regarding the risk of [[tumor]] rupture and subsequent [[peritoneal]] dissemination.  
* In GIST,  lymph node metastasis is rare and therefore lymphadenectomy and extensive lymph node exploration is rarely required.  
* In GIST,  [[lymph node]] [[metastasis]] is rare and therefore [[lymphadenectomy]] and extensive [[lymph node]] exploration is rarely required.  


* Most small GISTs (<5 and especially <2 cm) with a low rate of [[mitosis]] (<5 dividing cells per 50 high-power fields) are [[benign]] and, after surgery, do not require [[adjuvant therapy]].
* Most small GISTs (<5 and especially <2 cm) with a low rate of [[mitosis]] (<5 dividing cells per 50 high-power fields) are [[benign]] and, after surgery, do not require [[adjuvant therapy]] with [[tyrosine kinase inhibitors]].


* Larger GISTs (>5 cm), and especially when the cell division rate is high (>6 [[mitosis|mitoses]]/50 HPF), may disseminate and/or recur.
* Larger GISTs (>5 cm), and especially when the cell division rate is high (>6 [[mitosis|mitoses]]/50 HPF), may disseminate and/or recur and may be treated with [[tyrosine kinase inhibitors]].


* Previously GIST were resistant to conventional [[chemotherapy]] and had a mere success rate of <5%.
* Previously GIST were resistant to conventional [[chemotherapy]] and had a mere success rate of <5%.
* With the advent of ''c-kit'' [[tyrosine kinase]] inhibitor [[imatinib]] the treatment and response rate has gone up from 5% to 40-70% in metastatic or inoperable cases.<ref>{{Cite web | title =Gastrointestinal Stromal Tumors Treatment
* With the advent of ''c-kit'' [[tyrosine kinase]] inhibitor such as [[imatinib]], the response rate has gone up from 5% to 40-70% in metastatic or inoperable cases.<ref>{{Cite web | title =Gastrointestinal Stromal Tumors Treatment
| url =http://www.cancer.gov/types/soft-tissue-sarcoma/hp/gist-treatment-pdq#section/_35}}</ref>
| url =http://www.cancer.gov/types/soft-tissue-sarcoma/hp/gist-treatment-pdq#section/_35}}</ref>



Revision as of 15:22, 18 December 2017


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Akshun Kalia M.B.B.S.[2]Parminder Dhingra, M.D. [3]

Gastrointestinal stromal tumor Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Epidemiology and Demographics

Risk Factors

Screening

Differentiating Gastrointestinal stromal tumor from other Diseases

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Gastrointestinal stromal tumor surgery On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Gastrointestinal stromal tumor surgery

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Gastrointestinal stromal tumor surgery

CDC on Gastrointestinal stromal tumor surgery

Gastrointestinal stromal tumor surgery in the news

Blogs on Gastrointestinal stromal tumor surgery

Directions to Hospitals Treating Gastrointestinal stromal tumor

Risk calculators and risk factors for Gastrointestinal stromal tumor surgery

Overview

The predominant therapy for gastrointestinal stromal tumor (GIST) is surgical resection. Surgical resection offers an opportunity to completely cure GIST. Laparoscopic and endoscopic resection are the most preferred route of surgery. Surgical resection of GIST include complete gross resection with an intact pseudocapsule and negative microscopic margins.

Surgical Therapy

Surgery is the definitive therapy and typically the initial therapy for patients of gastrointestinal stromal tumor (GIST).

  • Surgical resection offers an opportunity to completely cure GIST.
  • Laparoscopic and endoscopic resection are the most preferred route of surgery. The indications for surgery include:[1][2][3][4]
    • Symptomatic patients with locally advanced disease.
    • Large lesions and tumors that are technically resectable if the risks of morbidity are acceptable.
  • Larger GISTs (>5 cm), and especially when the cell division rate is high (>6 mitoses/50 HPF), may disseminate and/or recur and may be treated with tyrosine kinase inhibitors.
  • Previously GIST were resistant to conventional chemotherapy and had a mere success rate of <5%.
  • With the advent of c-kit tyrosine kinase inhibitor such as imatinib, the response rate has gone up from 5% to 40-70% in metastatic or inoperable cases.[5]

References

  1. Liang JW, Zheng ZC, Zhang JJ, Zhang T, Zhao Y, Yang W, Liu YQ (2013). "Laparoscopic versus open gastric resections for gastric gastrointestinal stromal tumors: a meta-analysis". Surg Laparosc Endosc Percutan Tech. 23 (4): 378–87. doi:10.1097/SLE.0b013e31828e3e9d. PMID 23917593.
  2. DE Vogelaere K, VAN DE Winkel N, Simoens C, Delvaux G (2013). "Intragastric SILS for GIST, a new challenge in oncologic surgery: first experiences". Anticancer Res. 33 (8): 3359–63. PMID 23898104. Vancouver style error: missing comma (help)
  3. De Vogelaere K, Hoorens A, Haentjens P, Delvaux G (2013). "Laparoscopic versus open resection of gastrointestinal stromal tumors of the stomach". Surg Endosc. 27 (5): 1546–54. doi:10.1007/s00464-012-2622-8. PMID 23233005.
  4. Ye L, Wu X, Wu T, Wu Q, Liu Z, Liu C, Li S, Chen T (2017). "Meta-analysis of laparoscopic vs. open resection of gastric gastrointestinal stromal tumors". PLoS ONE. 12 (5): e0177193. doi:10.1371/journal.pone.0177193. PMC 5423634. PMID 28486486.
  5. "Gastrointestinal Stromal Tumors Treatment".


Template:WikiDoc Sources